{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:15:16Z","timestamp":1790111716229,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topical ruxolitinib was recently approved by the US Food and Drug Administration for the treatment of vitiligo. Studies comparing other topical Janus kinase inhibitors with established topical therapies like tacrolimus are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy and tolerability of topical tofacitinib and topical tacrolimus in patients with localized vitiligo using patient- and investigator-reported outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective randomized investigator-blinded intraindividual single-centre comparative trial conducted over 16 weeks between January and December 2024. Thirty patients with 60 symmetrical vitiligo patches were enrolled. Eligible participants had slowly spreading, nonsegmental vitiligo affecting \u2264 5% of their body surface area. Patches were randomized to receive either topical tofacitinib 2% ointment or topical tacrolimus 0.1% ointment twice daily for 16 weeks. The primary outcome was percentage of patches achieving treatment success, defined as a Vitiligo Noticeability Scale (VNS) score of 4 (\u2018a lot less noticeable\u2019) or 5 (\u2018no longer noticeable\u2019). Secondary outcomes included time to treatment success, trends of VNS among groups, extent of repigmentation and adverse effects. The study was registered with the Clinical Trial Registry of India (CTRI\/2023\/12\/060431).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the patches treated with tofacitinib, 47% (n = 14\/30) achieved treatment success vs. 37% (n = 11\/30) of those treated with tacrolimus (P = 0.60). The median time to treatment success was shorter for patches treated with tofacitinib [8 weeks; 95% confidence interval (CI) 4.333\u201311.667] than for those treated with tacrolimus [12 weeks; 95% CI 8.301\u201315.699 (P = 0.18)]. Significant repigmentation was seen with both treatments, with 33% (n = 10) of tofacitinib-treated patches and 20% (n = 6) of those treated with tacrolimus achieving &amp;gt; 80% repigmentation. There were fewer adverse events with tofacitinib (n = 2) than with tacrolimus (n = 7). Facial lesions responded better than acral or trunk lesions with both treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Topical tofacitinib demonstrated comparable efficacy to tacrolimus for localized vitiligo but showed trends toward earlier patient-reported response and a more favourable safety profile, a finding that could be validated in future studies with larger sample sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf306","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T11:52:06Z","timestamp":1753530726000},"page":"1112-1119","source":"Crossref","is-referenced-by-count":7,"title":["Comparative efficacy of topical tofacitinib versus topical tacrolimus in the treatment of localized vitiligo: a randomized investigator-blinded intraindividual trial"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-2330","authenticated-orcid":false,"given":"Hitaishi","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-1103","authenticated-orcid":false,"given":"Anuradha","family":"Bishnoi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4988","authenticated-orcid":false,"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-101X","authenticated-orcid":false,"given":"Muthu Sendhil","family":"Kumaran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-0815","authenticated-orcid":false,"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025111813172056500_ljaf306-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/gepi.1370020107","article-title":"Studies on vitiligo. I. Epidemiological profile in Calcutta, India","volume":"2","author":"Das","year":"1985","journal-title":"Genet Epidemiol"},{"key":"2025111813172056500_ljaf306-B2","first-page":"51","article-title":"400 cases of vitiligo. A clinico-therapeutic analysis","volume":"17","author":"Behl","year":"1972","journal-title":"Indian J Dermatol"},{"key":"2025111813172056500_ljaf306-B3","doi-asserted-by":"crossref","first-page":"e13418","DOI":"10.1111\/dth.13418","article-title":"Psychodermatology of vitiligo: psychological impact and consequences","volume":"33","author":"Simons","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025111813172056500_ljaf306-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025111813172056500_ljaf306-B5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2019.07.108","article-title":"The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis","volume":"82","author":"Chang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2025111813172056500_ljaf306-B6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025111813172056500_ljaf306-B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ajd.13572","article-title":"Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib","volume":"62","author":"Yagi","year":"2021","journal-title":"Australas J Dermatol"},{"key":"2025111813172056500_ljaf306-B8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025111813172056500_ljaf306-B9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2019.07.108","article-title":"The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis","volume":"82","author":"Chang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2025111813172056500_ljaf306-B10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/ced\/llad188","article-title":"Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review","volume":"48","author":"Dogra","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2025111813172056500_ljaf306-B11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.17013","article-title":"International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation","volume":"180","author":"Eleftheriadou","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025111813172056500_ljaf306-B12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025111813172056500_ljaf306-B13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025111813172056500_ljaf306-B14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient","volume":"13","author":"Berbert Ferreira","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"2025111813172056500_ljaf306-B15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/09546634.2020.1716930","article-title":"Combined microneedling with tacrolimus vs tacrolimus monotherapy for vitiligo treatment","volume":"32","author":"Ebrahim","year":"2021","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2025111813172056500_ljaf306-B16","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","article-title":"Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study","volume":"141","author":"Seneschal","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025111813172056500_ljaf306-B17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1468-3083.2009.03138.x","article-title":"Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial","volume":"23","author":"Radakovic","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813172056500_ljaf306-B18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1684\/ejd.2009.0779","article-title":"An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo","volume":"19","author":"Stinco","year":"2009","journal-title":"Eur J Dermatol"},{"key":"2025111813172056500_ljaf306-B19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71% vs. clobetasol propionate 0\u00b705% in childhood vitiligo","volume":"165","author":"Ho","year":"2011","journal-title":"Br J Dermatol"},{"key":"2025111813172056500_ljaf306-B20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4103\/ijd.ijd_461_23","article-title":"Development of consensus recommendations on the management of vitiligo and the role of decapeptide in vitiligo by the Delphi method","volume":"68","author":"Parsad","year":"2023","journal-title":"Indian J Dermatol"},{"key":"2025111813172056500_ljaf306-B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025111813172056500_ljaf306-B22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ced.15024","article-title":"Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study","volume":"47","author":"Salava","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025111813172056500_ljaf306-B23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2025111813172056500_ljaf306-B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5021\/ad.2019.31.1.90","article-title":"Incidence of topical tacrolimus adverse effects in chronic skin disease","volume":"31","author":"Park","year":"2019","journal-title":"Ann Dermatol"},{"key":"2025111813172056500_ljaf306-B25","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.2147\/CCID.S455602","article-title":"Topical tacrolimus in vitiligo: consensus paper from the Pigmentary Disorders Society","volume":"17","author":"Sarkar","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf306\/63946771\/ljaf306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1112\/63946771\/ljaf306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1112\/63946771\/ljaf306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:32Z","timestamp":1763489852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1112\/8221959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf306","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,4]]}}}